secwatch.observer — SEC 8-K summary
======================================

Issuer:     enGene Therapeutics Inc. (ENGN)
CIK:        0001980845
Form:       8-K
Filed at:   2025-10-02T23:59:59+00:00
Accession:  0001193125-25-228351
Event type: other_material
Sentiment:  neutral
Materiality: 0.35
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

enGene amends CEO Ron Cooper's severance to 1.5x target bonus on change-in-control termination
--------------------------------------------------------------------------------

- Board approved amendment to Cooper Employment Agreement, effective October 2, 2025.
- CIC termination severance multiplier increased from 1.0x to 1.5x annual target bonus.
- Lump sum payment payable within 45 days of CIC termination, subject to compliance.
- Amendment recommended by Compensation Committee; full text to be filed in 10-K for FY ending Oct 31, 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1980845/000119312525228351/0001193125-25-228351-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1980845/000119312525228351/engn-20251002.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-228351

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer